Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1-Reference-Cited by-同舟云学术

Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1

Published:2014-12 Issue:24 Volume:24 Page:5704-5709
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Gazzard Lewis^ORCID,Appleton Brent,Chapman Kerry,Chen Huifen,Clark Kevin,Drobnick Joy,Goodacre Simon,Halladay Jason,Lyssikatos Joseph,Schmidt Stephen,Sideris Steve,Wiesmann Christian,Williams Karen,Wu Ping,Yen Ivana,Malek Shiva

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference18 articles.

1. Unleashing Chk1 in cancer therapy

2. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

3. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

4. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico approaches for drug repurposing in oncology: a scoping review;Frontiers in Pharmacology;2024-06-11

2. Functions and inhibitors of CHK1 in cancer therapy;Medicine in Drug Discovery;2024-06

3. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets;Cancers;2024-03-13

4. A Review on the Anticancer Activity of Carbazole-based Tricyclic Compounds;Current Medicinal Chemistry;2023-10-19

5. Asymmetric Synthesis of N ‐Fmoc‐( S )‐7‐aza‐tryptophan via Alkylation of Chiral Nucleophilic Glycine Equivalent;European Journal of Organic Chemistry;2021-06